Nature Reviews Rheumatology - Cell-bound proteins complement current screening options in patients with SLE. ... (SLE) is more informative of disease activity than monitoring serum C3 and C4 levels.

Should you wait to upgrade to the LG C4 OLED or simply snap up the LG C3 while it’s on sale? Here's what you need to know.

Complement activation is common in patients with systemic lupus erythematosus (SLE), resulting in hypocomplementemia and deposition of complement at sites of tissue damage. The availability of ...

In contrast, among those who had negative results on the test, only 10.3% had developed SLE by 2 years (P<0.0001), the researchers reported online in Lupus Science & Medicine.The authors noted ...

When individual organ systems were analyzed, decreases in C3 and C4 were associated with a concurrent increase in renal disease activity (OR 2.2, 95% CI 1.4-3.5 and OR 1.9, 95% CI 1.1-3.4 ...

Erythrocyte-bound C4d, a biomarker for systemic lupus erythematosus patented by Exagen Diagnostics, is useful in monitoring disease activity in patients with the condition, according to findings ...

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

A complement test is a blood test that measures the activity of a group of proteins in the bloodstream. It's often used to help monitor people being treated for autoimmune diseases like lupus and ...

Dive into the ultimate OLED showdown as we compare the LG C4 and C3 models. This video examines brightness levels, picture quality, and overall performance to help you determine which TV offers ...

Learn what the complement c3 test is and how it is done. Why do you need this test ... For example, lower levels of C3 and C4 are a sign of lupus. Decreased complement activity may also be due to ...

Investigators have identified characteristics that signal impending renal flares among patients with systemic lupus erythematosus (SLE). In a post-hoc analysis of 4 phase 3 clinical trials of ...

Low complement levels prior to pregnancy are associated with an increased risk for adverse outcomes, including stillbirth and fetal loss, among patients with antiphospholipid antibodies, according ...